Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Lupus ; 29(7): 671-675, 2020 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-32316844

RESUMO

Here, we review current hydroxychloroquine screening guidelines and controversies regarding specific screening tests and acceptance of the guidelines. Screening tests are described, and their predictive results are analysed, with special emphasis on early changes. Further research is needed to come to a conclusion about the efficacy of the new proposed dose.


Assuntos
Antirreumáticos/efeitos adversos , Hidroxicloroquina/efeitos adversos , Retina/efeitos dos fármacos , Doenças Retinianas/induzido quimicamente , Doenças Retinianas/diagnóstico , Academias e Institutos , Antirreumáticos/administração & dosagem , Eletrorretinografia , Humanos , Hidroxicloroquina/administração & dosagem , Guias de Prática Clínica como Assunto , Medição de Risco , Tomografia de Coerência Óptica , Estados Unidos , Campos Visuais
3.
Ophthalmol Ther ; 11(5): 1937-1950, 2022 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-35896888

RESUMO

In the United Arab Emirates, retinopathy has been shown to be present in 19% of the diabetic population, with diabetes identified in up to 40% of individuals aged over 55 years. Despite the prevalence of diabetic retinal diseases, there are no unified national guidelines on the management of diabetic macular edema (DME). These published guidelines are based on evidence taken from the literature and published trials of therapies, and consensus opinion of a representative expert panel with an interest in this condition, convened by the Emirates Society of Ophthalmology. The aim is to provide evidence-based, clinical guidance for the best management of different aspects of DME, with a special focus on vision-threatening diabetic retinopathy. Treatment should be initiated in patients with best-corrected visual acuity 20/30 or worse, and/or features of DME as seen on optical coherence tomography (OCT) with central retinal thickness (CRT) of at least 300 µm or in symptomatic patients with vision better than 20/25, and/or CRT less than 300 µm where there are OCT features consistent with center-involving macular edema. The treatment of DME is effective irrespective of glycated hemoglobin (HbA1c) level, and treatment must not be denied or delayed in order to optimize systemic parameters. All ophthalmic treatment options should be discussed with the patient for better compliance and expectations. Non-center-involving DME can be initially observed until progression toward the center is documented. Macular laser no longer has a primary role in center-involving DME, and anti-vascular endothelial growth factor (anti-VEGF) therapy should be considered as first-line treatment for all patients, unless contraindicated. If anti-VEGF is contraindicated, a steroid dexamethasone implant can be considered for first-line treatment. Recommendations for the treatment of DME in special circumstances and in relapsing and refractory DME are also discussed.

SELEÇÃO DE REFERÊNCIAS
Detalhe da pesquisa